Production of recombinant peanut allergen Ara h 2 using Lactococcus lactis
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Production of recombinant peanut allergen Ara h 2 using Lactococcus lactis. / Glenting, Jacob; Poulsen, Lars K.; Kato, Kentaro; Madsen, Søren; Frøkiær, Hanne; Wendt, Camilla; Sørensen, Helle W.
I: Microbial Cell Factories, Bind 6, 28, 2007.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Production of recombinant peanut allergen Ara h 2 using Lactococcus lactis
AU - Glenting, Jacob
AU - Poulsen, Lars K.
AU - Kato, Kentaro
AU - Madsen, Søren
AU - Frøkiær, Hanne
AU - Wendt, Camilla
AU - Sørensen, Helle W
PY - 2007
Y1 - 2007
N2 - Natural allergen sources can supply large quantities of authentic allergen mixtures for use as immunotherapeutics. However, such extracts are complex, difficult to define, vary from batch to batch, which may lead to unpredictable efficacy and/or unacceptable levels of side effects. The use of recombinant expression systems for allergen production can alleviate some of these issues. Several allergens have been tested in high-level expression systems and in most cases show immunereactivity comparable to their natural counterparts. The gram positive lactic acid bacterium Lactococcus lactis is an attractive microorganism for use in the production of protein therapeutics. L. lactis is considered food grade, free of endotoxins, and is able to secrete the heterologous product together with few other native proteins. Hypersensitivity to peanut represents a serious allergic problem. Some of the major allergens in peanut have been described. However, for therapeutic usage more information about the individual allergenic components is needed. In this paper we report recombinant production of the Ara h 2 peanut allergen using L. lactis.
AB - Natural allergen sources can supply large quantities of authentic allergen mixtures for use as immunotherapeutics. However, such extracts are complex, difficult to define, vary from batch to batch, which may lead to unpredictable efficacy and/or unacceptable levels of side effects. The use of recombinant expression systems for allergen production can alleviate some of these issues. Several allergens have been tested in high-level expression systems and in most cases show immunereactivity comparable to their natural counterparts. The gram positive lactic acid bacterium Lactococcus lactis is an attractive microorganism for use in the production of protein therapeutics. L. lactis is considered food grade, free of endotoxins, and is able to secrete the heterologous product together with few other native proteins. Hypersensitivity to peanut represents a serious allergic problem. Some of the major allergens in peanut have been described. However, for therapeutic usage more information about the individual allergenic components is needed. In this paper we report recombinant production of the Ara h 2 peanut allergen using L. lactis.
U2 - 10.1186/1475-2859-6-28
DO - 10.1186/1475-2859-6-28
M3 - Journal article
C2 - 17711578
VL - 6
JO - Microbial Cell
JF - Microbial Cell
SN - 1475-2859
M1 - 28
ER -
ID: 43535155